Skip to main content
Premium Trial:

Request an Annual Quote

GenomeNext Raises $1.2M in Seed Financing

NEW YORK (GenomeWeb) – Genomic informatics company GenomeNext announced today that it has raised $1.2 million in seed funding led by Hydra Capital and private investors.

The company officially opened its doors in March 2014, and released its first product in January 2015 — a proprietary cloud-based data analysis pipeline that scientists in research and clinical contexts can use to process, analyze, and annotate variants in whole-genome, exome, and targeted panel.

GenomeNext was founded to commercialize computational technology developed by researchers at the Nationwide Children's Hospital in Columbus, Ohio for quickly and efficiently analyzing large quantities of genomic information. The company licensed the technology from the hospital.

More recently, GenomeNext benchmarked a timeframe for the analysis of a massive quantity of genomic data demonstrating population-scale capability. The firm analyzed the whole genomes and exomes of 2,504 individuals sampled across 26 different populations in one week, processing 1,000 samples per day, and generating close to 100 terabytes of processed result files.

The firm plans to use the seed funding to expand its existing sales infrastructure and marketing initiatives, and to continue developing products.

"This funding will enable GenomeNext to expand our commercial and operational capacity, facilitate continued evolution of our genomic analysis platform, and further our commitment to deliver increased value and utility to successfully address the computational and big-data complexities inherent in genomic medicine," said Co-founder and CEO James Hirmas in a statement.

The Scan

Nucleotide Base Detected on Near-Earth Asteroid

Among other intriguing compounds, researchers find the nucleotide uracil, a component of RNA sequences, in samples collected from the near-Earth asteroid Ryugu, as they report in Nature Communications.

Clinical Trial Participants, Investigators Point to Importance of Clinical Trial Results Reporting in Canadian Study

Public reporting on clinical trial results is crucial, according to qualitative interviews with clinical trial participants, investigators, and organizers from three provinces appearing in BMJ Open.

Old Order Amish Analysis Highlights Autozygosity, Potential Ties to Blood Measures

Researchers in BMC Genomics see larger and more frequent runs-of-homozygosity in Old Order Amish participants, though only regional autozygosity coincided with two blood-based measures.

Suicidal Ideation-Linked Loci Identified Using Million Veteran Program Data

Researchers in PLOS Genetics identify risk variants within and across ancestry groups with a genome-wide association study involving veterans with or without a history of suicidal ideation.